Surufatinib + envafolimab is flagged as watchlist signal because public records show timeline staleness. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Indication: Efficacy and Safety of Surufatinib Combined With Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients
Mechanism: Unknown
Modality: Unknown
Sponsor: Peking Union Medical College Hospital
Registry: 1/5
Timeline: 2/5
Recruitment burden: 0/5
Results availability: 0/5
Program risk: 2/5
https://clinicaltrials.gov/study/NCT05722977
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT05722977 | Low Signal (NOT_YET_RECRUITING) | stale_update_signal | long_recruitment_duration_signal | Low Signal | None |